Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin

• Published in: Atherosclerosis Vol. 257; pp. 164 - 171
• Main Authors: Panes, Olga, González, César, Hidalgo, Patricia, Valderas, Juan P., Acevedo, Mónica, Contreras, Susana, Sánchez, Ximena, Pereira, Jaime, Rigotti, Attilio, Mezzano, Diego
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.02.2017
• Subjects: Adult; Aged; Atorvastatin Calcium - therapeutic use; Biomarkers - blood; Blood Coagulation - drug effects; Blood Platelets - drug effects; Blood Platelets - metabolism; Cardiovascular; Cell Membrane - drug effects; Cell Membrane - genetics; Chile; Cholesterol - blood; Cholesterol, HDL - blood; Coagulation; Factor Xa - metabolism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia; Hypercholesterolemia - blood; Hypercholesterolemia - diagnosis; Hypercholesterolemia - drug therapy; Male; Middle Aged; Platelet Aggregation - drug effects; Platelet Glycoprotein GPIb-IX Complex - metabolism; Platelets; Rosuvastatin Calcium - therapeutic use; Statins; Thromboplastin - metabolism; Thrombosis; Time Factors; Tissue factor; Treatment Outcome; Hypercholesterolemia; Platelets; Thrombosis; Statins; Tissue factor; Coagulation

High plasma LDL-cholesterol (LDL-C) and platelet responses have major pathogenic roles in atherothrombosis. Thus, statins and anti-platelet drugs constitute mainstays in cardiovascular prevention/treatment. However, the role of platelet tissue factor-dependent procoagulant activity (TF-PCA) has rema...